DE2907778A1 - Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen - Google Patents
Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungenInfo
- Publication number
- DE2907778A1 DE2907778A1 DE19792907778 DE2907778A DE2907778A1 DE 2907778 A1 DE2907778 A1 DE 2907778A1 DE 19792907778 DE19792907778 DE 19792907778 DE 2907778 A DE2907778 A DE 2907778A DE 2907778 A1 DE2907778 A1 DE 2907778A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- use according
- fatty acid
- phosphatidylic
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 60
- 230000008447 perception Effects 0.000 title claims description 10
- 229940126601 medicinal product Drugs 0.000 title claims description 4
- 239000002253 acid Substances 0.000 claims description 48
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 244000068988 Glycine max Species 0.000 claims description 16
- 235000010469 Glycine max Nutrition 0.000 claims description 16
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 15
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 15
- 208000016285 Movement disease Diseases 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 208000022540 Consciousness disease Diseases 0.000 claims description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 6
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000002969 egg yolk Anatomy 0.000 claims description 4
- 235000013345 egg yolk Nutrition 0.000 claims description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 claims 1
- 241000282941 Rangifer tarandus Species 0.000 claims 1
- 208000030499 combat disease Diseases 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 34
- 206010021118 Hypotonia Diseases 0.000 description 29
- 230000036640 muscle relaxation Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 24
- 210000003710 cerebral cortex Anatomy 0.000 description 23
- 230000008859 change Effects 0.000 description 21
- 210000003414 extremity Anatomy 0.000 description 21
- 239000002775 capsule Substances 0.000 description 20
- 230000006378 damage Effects 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 230000037007 arousal Effects 0.000 description 16
- 230000001960 triggered effect Effects 0.000 description 16
- 230000004936 stimulating effect Effects 0.000 description 13
- 210000001364 upper extremity Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 235000019445 benzyl alcohol Nutrition 0.000 description 8
- 210000000133 brain stem Anatomy 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004899 motility Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 4
- -1 lecithins Chemical class 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000004291 polyenes Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960001637 meclofenoxate hydrochloride Drugs 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GOLSFPMYASLXJC-UHFFFAOYSA-N 2-(dimethylamino)ethyl acetate Chemical compound CN(C)CCOC(C)=O GOLSFPMYASLXJC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YXXZFSUFYRDVBI-UHFFFAOYSA-N 2H-pyran-2-ide-5-carbaldehyde Chemical compound O=CC1=CC=CO[CH-]1 YXXZFSUFYRDVBI-UHFFFAOYSA-N 0.000 description 1
- ZQKGKAKJYABQAK-UHFFFAOYSA-N 4-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=CC(CO)=C1O ZQKGKAKJYABQAK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- XWJTYEGVQBFZHI-IMPNNSMHSA-N Apocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1C2=C2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 XWJTYEGVQBFZHI-IMPNNSMHSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OBXRDFNCKFWKNY-MAZCIEHSSA-N [2-[(9z,12z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC OBXRDFNCKFWKNY-MAZCIEHSSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229960004986 pyritinol Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2238578A JPS54117034A (en) | 1978-02-28 | 1978-02-28 | Treating agent for consciousness and perception motion disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2907778A1 true DE2907778A1 (de) | 1979-08-30 |
| DE2907778C2 DE2907778C2 (cg-RX-API-DMAC7.html) | 1990-09-06 |
Family
ID=12081179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792907778 Granted DE2907778A1 (de) | 1978-02-28 | 1979-02-28 | Verwendung von phosphatidylverbindungen in arzneimitteln gegen wahrnehmungs-, bewusstseins- und bewegungsstoerungen |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4263286A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS54117034A (cg-RX-API-DMAC7.html) |
| DE (1) | DE2907778A1 (cg-RX-API-DMAC7.html) |
| NL (1) | NL7901601A (cg-RX-API-DMAC7.html) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2464715A1 (fr) * | 1979-09-14 | 1981-03-20 | Lpb Ist Farm | Utilisation de derives de glycerylphosphoryle dans la therapie des dyslipemies, des hepatites et des etats pathologiques analogues et compositions pharmaceutiques pour cette therapie |
| DE3228629A1 (de) * | 1982-07-31 | 1984-02-02 | Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß | Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung |
| EP0040039B1 (en) * | 1980-05-08 | 1984-08-01 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives of ammonioethyl phosphate, their production and use |
| EP0147735A3 (en) * | 1983-12-22 | 1985-11-27 | A. Nattermann & Cie. Gmbh | Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases |
| EP0147741A3 (en) * | 1983-12-22 | 1985-12-04 | A. Nattermann & Cie. Gmbh | Pharmaceutical composition with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of diseases of the stomach and the intestines |
| WO1988007860A1 (en) * | 1987-04-08 | 1988-10-20 | Riace Establishment | Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes |
| EP0389667A3 (en) * | 1989-03-07 | 1990-10-10 | Pharmacaps, Inc. | Use of lecithin to restore olfaction and taste |
| WO1994003180A1 (en) * | 1992-07-30 | 1994-02-17 | Prime European Therapeuticals S.P.A. | Pharmacologically active glycerophosphoderivatives |
| EP0656782A4 (en) * | 1992-07-27 | 1995-09-06 | Abbott Lab | NUTRITIONAL PRODUCT FOR PEOPLE WITH NEUROLOGICAL LESIONS. |
| WO2005037848A3 (en) * | 2003-10-22 | 2005-05-26 | Enzymotec Ltd | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5566512A (en) * | 1978-11-15 | 1980-05-20 | Massachusetts Inst Technology | Method and composition for treating difficulties by administration of choline or choline dissociating compound |
| JPS55115824A (en) * | 1979-02-28 | 1980-09-06 | Nippon Shoji Kk | Remedy for clouding of consciousness and sensomobile disorder |
| US4677099A (en) * | 1981-09-04 | 1987-06-30 | Yeda Research And Development Co., Ltd. | Medical processes employing a novel lipid fraction |
| IL63734A (en) * | 1981-09-04 | 1985-07-31 | Yeda Res & Dev | Lipid fraction,its preparation and pharmaceutical compositions containing same |
| US4666893A (en) * | 1983-02-15 | 1987-05-19 | St. Thomas Institute | Methods of inducing resistance to bacterial and viral infections |
| US4921706A (en) * | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US5011964A (en) * | 1985-03-07 | 1991-04-30 | Cornell Research Foundation, Inc. | Novel diacylglycerophosphoric acid esters and use thereof as substrates in enzyme assays |
| IT1199972B (it) * | 1985-05-08 | 1989-01-05 | Lpb Ist Farm | Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale |
| US4923854A (en) * | 1986-01-22 | 1990-05-08 | The Liposome Company, Inc. | Solubilization of hydrophobic materials using lysophospholipid |
| US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| IL118180A (en) * | 1996-05-08 | 2000-12-06 | Modus Biolog Membranes Ltd | Pharmaceutical compositions comprising a phosphatidic acid (PA) enriched natural phospholipid preparation and the production of such preparation |
| US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| IL121322A (en) * | 1997-07-16 | 2002-07-25 | Modus Biolog Membranes Ltd | Modular pharmacological preparation of the immune system based on fats and its preparation |
| US6949528B1 (en) | 1998-03-18 | 2005-09-27 | Goddard John G | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| AU1029500A (en) * | 1998-08-29 | 2000-03-21 | Miklos Ghyczy | Pharmaceutical and/or diet product |
| US6592910B1 (en) * | 1999-04-20 | 2003-07-15 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
| CA2380640A1 (en) * | 1999-08-18 | 2001-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Hair-growing agent |
| US20060063738A1 (en) * | 2000-02-28 | 2006-03-23 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| US6683066B2 (en) | 2001-09-24 | 2004-01-27 | Yanming Wang | Composition and treatment method for brain and spinal cord injuries |
| US7691417B2 (en) | 2004-09-02 | 2010-04-06 | Clemson University Research Foundation | Tumor and mutation suppressing plant extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3772360A (en) * | 1969-07-01 | 1973-11-13 | Smithkline Corp | Adamantyl substituted glycerophosphoryl(and phosphonyl)ethanolamines |
-
1978
- 1978-02-28 JP JP2238578A patent/JPS54117034A/ja active Granted
-
1979
- 1979-02-28 NL NL7901601A patent/NL7901601A/xx not_active Application Discontinuation
- 1979-02-28 DE DE19792907778 patent/DE2907778A1/de active Granted
-
1980
- 1980-05-05 US US06/146,215 patent/US4263286A/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| Mitt. dt. pharm. Gesellsch., 33. Jg., Nr. 2, S. 35-36, 1963 * |
| RÖMPP: Chemie-Lexikon, 6. Aufl. Sp. 3630 u. 7. Aufl. S. 1946-1947, 1973 * |
| Seifen, Öle, Fette, Wachse, 96. Jg., S. 551-554, 1970 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2464715A1 (fr) * | 1979-09-14 | 1981-03-20 | Lpb Ist Farm | Utilisation de derives de glycerylphosphoryle dans la therapie des dyslipemies, des hepatites et des etats pathologiques analogues et compositions pharmaceutiques pour cette therapie |
| EP0040039B1 (en) * | 1980-05-08 | 1984-08-01 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives of ammonioethyl phosphate, their production and use |
| DE3228629A1 (de) * | 1982-07-31 | 1984-02-02 | Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß | Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung |
| EP0147735A3 (en) * | 1983-12-22 | 1985-11-27 | A. Nattermann & Cie. Gmbh | Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases |
| EP0147741A3 (en) * | 1983-12-22 | 1985-12-04 | A. Nattermann & Cie. Gmbh | Pharmaceutical composition with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of diseases of the stomach and the intestines |
| WO1988007860A1 (en) * | 1987-04-08 | 1988-10-20 | Riace Establishment | Pharmaceutical compositions for the treatment of cerebral psycho-organic syndromes |
| EP0389667A3 (en) * | 1989-03-07 | 1990-10-10 | Pharmacaps, Inc. | Use of lecithin to restore olfaction and taste |
| EP0656782A4 (en) * | 1992-07-27 | 1995-09-06 | Abbott Lab | NUTRITIONAL PRODUCT FOR PEOPLE WITH NEUROLOGICAL LESIONS. |
| WO1994003180A1 (en) * | 1992-07-30 | 1994-02-17 | Prime European Therapeuticals S.P.A. | Pharmacologically active glycerophosphoderivatives |
| WO2005037848A3 (en) * | 2003-10-22 | 2005-05-26 | Enzymotec Ltd | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| AU2004282006B2 (en) * | 2003-10-22 | 2010-04-15 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| AU2004282006C1 (en) * | 2003-10-22 | 2010-10-21 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| EP2258377A3 (en) * | 2003-10-22 | 2011-10-05 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
| US8470345B2 (en) | 2003-10-22 | 2013-06-25 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2907778C2 (cg-RX-API-DMAC7.html) | 1990-09-06 |
| JPS623127B2 (cg-RX-API-DMAC7.html) | 1987-01-23 |
| US4263286A (en) | 1981-04-21 |
| NL7901601A (nl) | 1979-08-30 |
| JPS54117034A (en) | 1979-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2907778C2 (cg-RX-API-DMAC7.html) | ||
| DE69111642T2 (de) | Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. | |
| DE69904208T2 (de) | Antioxidative mischung bestehend aus acetyl l-carnitin und alpha-liponsäure | |
| DE69632743T2 (de) | Verfahren zur regulierung des vagaltonus | |
| DE69230046T2 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
| DE3338995C2 (cg-RX-API-DMAC7.html) | ||
| DE69828881T2 (de) | Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen | |
| DE69118859T2 (de) | Behandlung von Schlafstörungen unter Verwendung bestimmter Antidepressiva, z.B. Nefazodon | |
| DE2903558A1 (de) | Therapeutisches verfahren zur behandlung von hyperlipoproteinaemie und hyperlipidaemie sowie arzneimittel zu seiner durchfuehrung | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE10349979B4 (de) | Medikamentöse gezielte lokale Lipolyse | |
| DE102010028365A1 (de) | Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| CH670952A5 (cg-RX-API-DMAC7.html) | ||
| DE3323264C2 (de) | Arzneimittel zur Behandlung von vaskulären Erkrankungen | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| GB2045612A (en) | Pharmaceutical compositions containing phosphatidic acids for the treatment of disorders of consciousness perception and movement | |
| DE2514335A1 (de) | Oral zu verabreichendes arzneimittel mit antiplasmin-inhibitorwirkung | |
| DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
| DE2527552A1 (de) | Mittel zur behandlung von krankheitszustaenden, die durch demyelierungsprozesse oder hypercholinergie bedingt werden | |
| DE3916417A1 (de) | Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid als aktive wirkstoffe | |
| DE3650735T2 (de) | Verwendung von Cholin oder Cholin freisetzenden Verbindungen zur Verringerung der Empfingdung von Ermüdung | |
| DE2660486C2 (de) | Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel | |
| DE3125512A1 (de) | L-arginin-d,l-pyroglutamat als auf neuroedokrinem gebiet wirksames mittel | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |